Company BerGenBio ASA

Equities

BGBIO

NO0010650013

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-25 am EDT			5-day change	1st Jan Change
0.156 ^NOK	0.00%		-3.58%	-43.88%

Mar. 20	Bergenbio Announces Initiation of Phase 2A in First Line Non-Small Lung Cancer Patients with A STK11 Mutation	CI
Feb. 14	BerGenBio ASA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Bergenbio ASA is a Norway-based clinical-stage biopharmaceutical company focused on developing drugs for aggressive diseases including cancer and severe respiratory infections. The Company's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The Company's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK.

Number of employees: 25

NOK in Million	2021	Weight	2022	Weight	Delta
Innovative Drugs 100.0 %	1	100.0 %	0	100.0 %	-49.74%

NOK in Million	2021	Weight	2022	Weight	Delta
Norway 100.0 %	1	100.0 %	0	100.0 %	-49.74%

Managers	Title	Age	Since
Martin Olin CEO	Chief Executive Officer	55	21-09-07
Rune Skeie DFI	Director of Finance/CFO	51	18-03-04
Nigel McCracken CTO	Chief Tech/Sci/R&D Officer	-	20-12-31
James Barnes COO	Chief Operating Officer	-	19-02-28
Cristina Oliva CTO	Chief Tech/Sci/R&D Officer	-	22-04-24
Debbie Molyneux HRO	Human Resources Officer	-	18-12-31
Gayle Mills PRN	Corporate Officer/Principal	69	20-12-31

Members of the board	Title	Age	Since
Sally Bennett BRD	Director/Board Member	52	20-12-08
Sveinung Hole BRD	Director/Board Member	57	10-08-31
Anders Lennart Tullgren CHM	Chairman	63	22-01-05
Debra Stephanie Barker BRD	Director/Board Member	61	19-03-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,688,689,214	1,252,671,941 ( 46.59 %)	0	46.59 %

Name	Equities	%	Valuation
Trond Mohn 32.73 %	880,114,786	32.73 %	16 M kr
Investinor AS 8.086 %	217,417,430	8.086 %	4 M kr
MP Pensjon PK 2.123 %	57,069,659	2.123 %	1 M kr
Magne Roar Sangolt 2.074 %	55,768,426	2.074 %	1 M kr
Marit Mohn 1.921 %	51,651,648	1.921 %	928 697 kr
Nordnet Livsforsikring AS 1.641 %	44,133,597	1.641 %	793 522 kr
Fjärde AP-fonden 1.455 %	39,113,922	1.455 %	703 268 kr
Jakob Hatteland 1.312 %	35,275,000	1.312 %	634 245 kr
Rongevær 1.130 %	30,369,946	1.130 %	546 052 kr
Sarsia Venture Management AS 1.022 %	27,477,391	1.022 %	494 043 kr

BerGenBio ASA

Møllendalsbakken 9

5867, Bergen

+47 55 96 11 59

http://www.bergenbio.com

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

0.156 NOK

Average target price

0.7667 NOK

Spread / Average Target

+391.46%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
BERGENBIO ASA	-43.88%	58.64M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs